NCT04123366: Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

NCT04123366
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be refractory to prior platinum therapy (e.g. cisplatin, carboplatin, or oxaliplatin)
Exclusions: Patients with either germline (genetic) or somatic BRCA mutation; Patients with known central nervous system (CNS) metastases and/or carcinomatous meningitis; Patients who received olaparib or any other PARP inhibitor, prior anti-PD-1/PD-L1/2), -CTLA4, -OX40 or -CD137 agent
https://ClinicalTrials.gov/show/NCT04123366

Comments are closed.

Up ↑